Twist Bioscience Corp (NASDAQ:TWST) Reports Mixed Q3 2025 Results with Revenue Miss and EPS Beat

Twist Bioscience Corp. (NASDAQ:TWST) reported its fiscal third-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The synthetic DNA manufacturer posted revenue of $96.06 million, falling short of the consensus estimate of $97.53 million. However, the company’s earnings per share (EPS) of -$0.47 outperformed the anticipated -$0.57, reflecting tighter cost controls and operational efficiency.

Key Financial Highlights

• Revenue Miss: Reported sales of $96.06 million were 1.5% below analyst expectations, marking a slight underperformance.
• EPS Beat: The company narrowed its losses, with EPS coming in at -$0.47 compared to the estimated -$0.57.
• Market Reaction: Shares dipped nearly 5% in pre-market trading, suggesting investor disappointment despite the EPS beat, likely due to the revenue shortfall.

Business and Operational Updates

CEO Emily M. Leproust emphasized the company’s disciplined cost management and strong balance sheet, which have helped sustain operations amid broader market challenges. Twist Bioscience continues to leverage its silicon-based DNA synthesis platform, serving industries such as healthcare, agriculture, and industrial chemicals.

Forward-Looking Estimates

Analysts project full-year 2025 revenue at $384.19 million, with Q4 sales expected to reach $101.16 million. The company did not provide explicit guidance in its press release, leaving investors to rely on external estimates.

Market Sentiment and Performance

The stock has seen modest declines over recent periods:

• Last Week: -0.06%
• Last Two Weeks: -0.04%
• Last Month: -11.76%

The pre-market drop following the earnings release indicates that investors may be weighing the revenue miss more heavily than the EPS improvement.

For a deeper dive into Twist Bioscience’s earnings and future estimates, visit the earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.